Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CERo Therapeutics Holdings, Inc. (CERO) SEC filings page on Stock Titan provides access to the company’s public reports and regulatory disclosures, along with AI-generated summaries to help interpret complex documents. As a clinical-stage biotechnology issuer and emerging growth company, CERo uses SEC filings to describe its immunotherapy platform, clinical programs, capital structure, and risk factors in detail.
Key filings for CERO include current reports on Form 8-K, which the company has used to announce material events such as Nasdaq listing determinations, private placements of Series E convertible preferred stock, equity line of credit agreements with institutional investors, and clinical or corporate presentations furnished under Regulation FD. These 8-Ks often provide timely information on financing terms, changes in trading venue, and progress of the CER-1236 program.
CERo’s registration statements on Form S-1 describe arrangements like its committed equity financing with an institutional investor, including the potential resale of large blocks of common stock issued under common stock purchase agreements. These documents outline how the company may raise capital over time and discuss associated risks and dilution considerations.
Other important disclosures include proxy materials on Schedule 14A, which have covered proposals such as a reverse stock split, increases to the 2024 Equity Incentive Plan share reserve, and approvals related to convertible preferred stock. Notifications like Form 12b-25 (NT 10-Q) explain delays in periodic reporting and provide preliminary financial information when applicable.
On this page, Stock Titan surfaces new CERO filings as they appear in the EDGAR system and applies AI to highlight key sections, such as clinical trial plans, financing covenants, listing status updates, and changes to capital structure. Users can quickly locate 10-K, 10-Q, S-1, 8-K, proxy statements, and other forms, while AI summaries help clarify technical language around preferred stock terms, equity lines, and regulatory or listing developments that may affect CERO shareholders.
CERO Therapeutics is supplementing its Form S-1 to register 729,596,950 shares of Common Stock via Prospectus Supplement No. 5.
The supplement attaches a Form 8-K disclosing a $750,000 convertible note (principal face value $937,500) that permits up to $1,000,000 of borrowings, bears 10% interest, matures on
The Form 8-K also reports dismissal of auditor Wolf & Company, P.C. and appointment of Salberg & Company, P.A. effective
CERO Therapeutics Holdings, Inc. entered into a financing agreement by issuing a convertible promissory note to Keystone Capital Partners for a $750,000 purchase price with a principal face value of $937,500, allowing total borrowings up to $1,000,000. The note bears 10% annual interest, matures on July 9, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership limit. The company plans to file a registration statement covering resale of conversion shares. CERO’s audit committee dismissed Wolf & Company, P.C. as independent auditor and appointed Salberg & Company, P.A., following prior audit reports that included a going concern explanatory paragraph and a material weakness in internal controls. The board also expanded from six to seven members and appointed Eric Francois as a new director, with an expectation he will stand for election at the 2026 annual meeting.
Cero Therapeutics Holdings, Inc. has registered 729,596,950 shares of common stock under a Form S-1, and this Prospectus Supplement No. 4 updates that registration by incorporating information from a newly filed Current Report on Form 8-K.
The 8-K adds a poster presentation that the company prepared for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026, filed as Exhibit 99.1. Cero’s common stock trades on OTCQB under “CERO” and its public warrants trade on OTCID under “CEROW.” On February 3, 2026, the last quoted bid prices were $0.05 per share of common stock and $0.0068 per warrant.
The company is classified as an emerging growth company and highlights that investing in its securities involves a high degree of risk, directing readers to the Risk Factors section of the base prospectus. The poster is described as summary information and is intended to be read together with the company’s other SEC filings and public announcements.
CERo Therapeutics Holdings, Inc. filed a current report to note that it has prepared a poster presentation for the Transplantation and Cellular Therapy Meetings beginning on February 4, 2026. The poster is included as Exhibit 99.1 and is described as summary information meant to be read alongside the company’s other SEC filings and public announcements.
The company states that the poster presentation speaks only as of its date and that it expressly disclaims any obligation to update it, even if circumstances change. The filing is administrative in nature and does not include financial results or major corporate transactions.
CERO Therapeutics Holdings, Inc. reported that the Nasdaq Listing and Hearing Review Council has affirmed a prior decision to delist the company’s securities from the Nasdaq Stock Market. The Council’s decision, dated January 29, 2026, upholds a panel ruling following an earlier trading suspension effective October 31, 2025.
This means the company’s common stock and related warrants will no longer trade on Nasdaq, which can affect trading liquidity and market visibility for shareholders. The filing does not describe any alternative listing venue in this excerpt.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.
Cero Therapeutics Holdings, Inc. reported that Chief Development Officer Kristen Pierce received a grant of stock options on 01/07/2026. The award covers 1,612,099 stock options, each representing the right to buy one share of common stock at an exercise price of $0.055 per share. Following this grant, Pierce beneficially owns 1,612,099 derivative securities, all held in direct ownership form.
CERO Therapeutics Holdings, Inc. reported that director Shami Patel received a stock option grant. On January 7, 2026, Patel was awarded an option to buy 690,900 shares of CERO common stock at an exercise price of $0.055 per share. The option is first exercisable on January 7, 2026 and expires on January 6, 2036. After this grant, Patel beneficially owns stock options covering 690,900 shares, held as a direct ownership position.
Cero Therapeutics Holdings director reports large stock option award
Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., reported receiving a stock option covering 1,612,099 shares of the company’s common stock. The option has an exercise price of $0.055 per share, meaning he can buy up to that number of shares at this fixed price.
The option became exercisable on January 7, 2026 and is scheduled to expire on January 6, 2036, giving a 10‑year exercise window. Following this transaction, Atwood beneficially owns 1,612,099 derivative securities in the form of this stock option, which is reported as held directly.